|
Cote has studied cancer detection and diagnosis throughout his career. In collaborative research, he developed guidelines to improve HER2 testing accuracy in invasive breast cancer, recommending standardized procedures and criteria to ensure reliable results for all cases.[{{Cite journal|url=https://meridian.allenpress.com/aplm/article/131/1/18/460033/American-Society-of-Clinical-Oncology-College-of|title=American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer|first1=Antonio C.|last1=Wolff|first2=M. Elizabeth H.|last2=Hammond|first3=Jared N.|last3=Schwartz|first4=Karen L.|last4=Hagerty|first5=D. Craig|last5=Allred|first6=Richard J.|last6=Cote|first7=Mitchell|last7=Dowsett|first8=Patrick L.|last8=Fitzgibbons|first9=Wedad M.|last9=Hanna|first10=Amy|last10=Langer|first11=Lisa M.|last11=McShane|first12=Soonmyung|last12=Paik|first13=Mark D.|last13=Pegram|first14=Edith A.|last14=Perez|first15=Michael F.|last15=Press|first16=Anthony|last16=Rhodes|first17=Catharine|last17=Sturgeon|first18=Sheila E.|last18=Taube|first19=Raymond|last19=Tubbs|first20=Gail H.|last20=Vance|first21=Marc|last21=van de Vijver|first22=Thomas M.|last22=Wheeler|first23=Daniel F.|last23=Hayes|date=January 1, 2007|journal=Archives of Pathology & Laboratory Medicine|volume=131|issue=1|pages=18–43|via=CrossRef|doi=10.5858/2007-131-18-ASOCCO|pmid=19548375 |url-access=subscription}}] He is one of the founders of the field of liquid biopsy for cancer detection and evaluation and published the first study on the US on disseminated tumor cells (DTC) focusing on patients with early stage breast cancer,[{{Cite journal|url=https://journals.lww.com/ajsp/abstract/1988/05000/monoclonal_antibodies_detect_occult_breast.1.aspx|title=Monoclonal Antibodies Detect Occult Breast Carcinoma Metastases in the Bone Marrow of Patients with Early Stage Disease|first1=Richard J.|last1=Cote|first2=Paul P.|last2=Rosen|first3=Thomas B.|last3=Hakes|first4=Mohamed|last4=Sedira|first5=Michel|last5=Bazinet|first6=David W.|last6=Kinne|first7=Lloyd J.|last7=Old|first8=Michael P.|last8=Osborne|date=May 31, 1988|journal=The American Journal of Surgical Pathology|volume=12|issue=5|pages=333–340|via=journals.lww.com|doi=10.1097/00000478-198805000-00001|pmid=3364618 |url-access=subscription}}] and followed this up with a study showing that such cells identify patients at increased risk for metastasis.[{{Cite journal|url=https://ascopubs.org/doi/10.1200/JCO.1991.9.10.1749|title=Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.|first1=R J|last1=Cote|first2=P P|last2=Rosen|first3=M L|last3=Lesser|first4=L J|last4=Old|first5=M P|last5=Osborne|date=October 31, 1991|journal=Journal of Clinical Oncology|volume=9|issue=10|pages=1749–1756|via=CrossRef|doi=10.1200/JCO.1991.9.10.1749|pmid=1919627 |url-access=subscription}}] He later worked with Munro Neville and the Ludwig Institute to publish a study showing that identification of occult tumor cells in the lymph nodes of patients with early-stage breast cancer identify those with increased risk for metastasis.[{{Cite journal|title=Role of immunohistochemical detection of lymph-node metastases in management of breast cancer|first1=RJ|last1=Cote|first2=H|last2=Fpeterson|first3=B|last3=Chaiwun|first4=RD|last4=Gelber|first5=A|last5=Goldhirsch|first6=M|last6=Castiglione-Gertsch|first7=B|last7=Gusterson|first8=AM|last8=Neville|date=September 30, 1999|journal=The Lancet|volume=354|issue=9182|pages=896–900|doi=10.1016/s0140-6736(98)11104-2|pmid=10489948 }}] His work also revealed breast [[cancer stem cell]] phenotype in bone marrow disseminated tumor cells of early breast cancer patients, suggesting implications for metastasis and underscoring the need for further molecular analysis.[{{Cite journal|url=https://aacrjournals.org/clincancerres/article/12/19/5615/192961/Most-Early-Disseminated-Cancer-Cells-Detected-in|title=Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype|first1=Marija|last1=Balic|first2=Henry|last2=Lin|first3=Lillian|last3=Young|first4=Debra|last4=Hawes|first5=Armando|last5=Giuliano|first6=George|last6=McNamara|first7=Ram H.|last7=Datar|first8=Richard J.|last8=Cote|date=October 1, 2006|journal=Clinical Cancer Research|volume=12|issue=19|pages=5615–5621|via=CrossRef|doi=10.1158/1078-0432.CCR-06-0169|pmid=17020963 }}] Additionally, he introduced a parylene membrane microfilter device for quick and efficient capture and analysis of circulating tumor cells (CTCs) in human blood.[{{Cite journal|title=Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells|first1=Siyang|last1=Zheng|first2=Henry|last2=Lin|first3=Jing-Quan|last3=Liu|first4=Marija|last4=Balic|first5=Ram|last5=Datar|first6=Richard J.|last6=Cote|first7=Yu-Chong|last7=Tai|date=August 31, 2007|journal=Journal of Chromatography A|volume=1162|issue=2|pages=154–161|doi=10.1016/j.chroma.2007.05.064|pmid=17561026 }}] |
|
Cote has studied cancer detection and diagnosis throughout his career. In collaborative research, he developed guidelines to improve HER2 testing accuracy in invasive breast cancer, recommending standardized procedures and criteria to ensure reliable results for all cases.[{{Cite journal|url=https://meridian.allenpress.com/aplm/article/131/1/18/460033/American-Society-of-Clinical-Oncology-College-of|title=American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer|first1=Antonio C.|last1=Wolff|first2=M. Elizabeth H.|last2=Hammond|first3=Jared N.|last3=Schwartz|first4=Karen L.|last4=Hagerty|first5=D. Craig|last5=Allred|first6=Richard J.|last6=Cote|first7=Mitchell|last7=Dowsett|first8=Patrick L.|last8=Fitzgibbons|first9=Wedad M.|last9=Hanna|first10=Amy|last10=Langer|first11=Lisa M.|last11=McShane|first12=Soonmyung|last12=Paik|first13=Mark D.|last13=Pegram|first14=Edith A.|last14=Perez|first15=Michael F.|last15=Press|first16=Anthony|last16=Rhodes|first17=Catharine|last17=Sturgeon|first18=Sheila E.|last18=Taube|first19=Raymond|last19=Tubbs|first20=Gail H.|last20=Vance|first21=Marc|last21=van de Vijver|first22=Thomas M.|last22=Wheeler|first23=Daniel F.|last23=Hayes|date=January 1, 2007|journal=Archives of Pathology & Laboratory Medicine|volume=131|issue=1|pages=18–43|via=CrossRef|doi=10.5858/2007-131-18-ASOCCO|pmid=19548375 |url-access=subscription}}] He is one of the founders of the field of [[liquid biopsy]] for cancer detection and evaluation and published the first study on the US on disseminated tumor cells (DTC) focusing on patients with early stage breast cancer,[{{Cite journal|url=https://journals.lww.com/ajsp/abstract/1988/05000/monoclonal_antibodies_detect_occult_breast.1.aspx|title=Monoclonal Antibodies Detect Occult Breast Carcinoma Metastases in the Bone Marrow of Patients with Early Stage Disease|first1=Richard J.|last1=Cote|first2=Paul P.|last2=Rosen|first3=Thomas B.|last3=Hakes|first4=Mohamed|last4=Sedira|first5=Michel|last5=Bazinet|first6=David W.|last6=Kinne|first7=Lloyd J.|last7=Old|first8=Michael P.|last8=Osborne|date=May 31, 1988|journal=The American Journal of Surgical Pathology|volume=12|issue=5|pages=333–340|via=journals.lww.com|doi=10.1097/00000478-198805000-00001|pmid=3364618 |url-access=subscription}}] and followed this up with a study showing that such cells identify patients at increased risk for metastasis.[{{Cite journal|url=https://ascopubs.org/doi/10.1200/JCO.1991.9.10.1749|title=Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.|first1=R J|last1=Cote|first2=P P|last2=Rosen|first3=M L|last3=Lesser|first4=L J|last4=Old|first5=M P|last5=Osborne|date=October 31, 1991|journal=Journal of Clinical Oncology|volume=9|issue=10|pages=1749–1756|via=CrossRef|doi=10.1200/JCO.1991.9.10.1749|pmid=1919627 |url-access=subscription}}] He later worked with Munro Neville and the Ludwig Institute to publish a study showing that identification of occult tumor cells in the lymph nodes of patients with early-stage breast cancer identify those with increased risk for metastasis.[{{Cite journal|title=Role of immunohistochemical detection of lymph-node metastases in management of breast cancer|first1=RJ|last1=Cote|first2=H|last2=Fpeterson|first3=B|last3=Chaiwun|first4=RD|last4=Gelber|first5=A|last5=Goldhirsch|first6=M|last6=Castiglione-Gertsch|first7=B|last7=Gusterson|first8=AM|last8=Neville|date=September 30, 1999|journal=The Lancet|volume=354|issue=9182|pages=896–900|doi=10.1016/s0140-6736(98)11104-2|pmid=10489948 }}] His work also revealed breast [[cancer stem cell]] phenotype in bone marrow disseminated tumor cells of early breast cancer patients, suggesting implications for metastasis and underscoring the need for further molecular analysis.[{{Cite journal|url=https://aacrjournals.org/clincancerres/article/12/19/5615/192961/Most-Early-Disseminated-Cancer-Cells-Detected-in|title=Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype|first1=Marija|last1=Balic|first2=Henry|last2=Lin|first3=Lillian|last3=Young|first4=Debra|last4=Hawes|first5=Armando|last5=Giuliano|first6=George|last6=McNamara|first7=Ram H.|last7=Datar|first8=Richard J.|last8=Cote|date=October 1, 2006|journal=Clinical Cancer Research|volume=12|issue=19|pages=5615–5621|via=CrossRef|doi=10.1158/1078-0432.CCR-06-0169|pmid=17020963 }}] Additionally, he introduced a parylene membrane microfilter device for quick and efficient capture and analysis of circulating tumor cells (CTCs) in human blood.[{{Cite journal|title=Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells|first1=Siyang|last1=Zheng|first2=Henry|last2=Lin|first3=Jing-Quan|last3=Liu|first4=Marija|last4=Balic|first5=Ram|last5=Datar|first6=Richard J.|last6=Cote|first7=Yu-Chong|last7=Tai|date=August 31, 2007|journal=Journal of Chromatography A|volume=1162|issue=2|pages=154–161|doi=10.1016/j.chroma.2007.05.064|pmid=17561026 }}] |
|
In a paper published in the ''New England Journal of Medicine'', Cote and colleagues identified nuclear p53 accumulation as an independent predictor of poor outcomes in bladder-confined transitional-cell carcinoma,[{{Cite journal|url=http://www.nejm.org/doi/abs/10.1056/NEJM199411103311903|title=Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer|first1=David|last1=Esrig|first2=Donald|last2=Elmajian|first3=Susan|last3=Groshen|first4=John A.|last4=Freeman|first5=John P.|last5=Stein|first6=Su-Chiu|last6=Chen|first7=Peter W.|last7=Nichols|first8=Donald G.|last8=Skinner|first9=Peter A.|last9=Jones|first10=Richard J.|last10=Cote|date=November 10, 1994|journal=New England Journal of Medicine|volume=331|issue=19|pages=1259–1264|via=CrossRef|doi=10.1056/NEJM199411103311903|pmid=7935683 }}] while also demonstrating genetic discrepancies between papillary and flat transitional cell carcinomas, indicating diverse pathways of tumor progression.[{{Cite web|url=https://aacrjournals.org/cancerres/article/54/3/784/500944/Two-Molecular-Pathways-to-Transitional-Cell|title=Two Molecular Pathways to Transitional Cell Carcinoma of the Bladder1 | Cancer Research | American Association for Cancer Research}}] He further showed that microcantilevers can detect [[prostate-specific antigen]] (PSA) in various concentrations, suggesting their potential for diagnosing prostate cancer and other diseases.[{{Cite journal|url=https://www.nature.com/articles/nbt0901-856|title=Bioassay of prostate-specific antigen (PSA) using microcantilevers|first1=Guanghua|last1=Wu|first2=Ram H.|last2=Datar|first3=Karolyn M.|last3=Hansen|first4=Thomas|last4=Thundat|first5=Richard J.|last5=Cote|first6=Arun|last6=Majumdar|date=September 30, 2001|journal=Nature Biotechnology|volume=19|issue=9|pages=856–860|via=www.nature.com|doi=10.1038/nbt0901-856|pmid=11533645 |url-access=subscription}}] Later, alongside Shan-Rong Shi and Clive Taylor, he reviewed the antigen retrieval technique in immunohistochemical staining, emphasizing the need for standardized protocols and optimal retrieval methods.[{{Cite journal|url=http://journals.sagepub.com/doi/10.1177/002215549704500301|title=Antigen Retrieval Immunohistochemistry: Past, Present, and Future|first1=Shan-Rong|last1=Shi|first2=Richard J.|last2=Cote|first3=Clive R.|last3=Taylor|date=March 31, 1997|journal=Journal of Histochemistry & Cytochemistry|volume=45|issue=3|pages=327–343|via=CrossRef|doi=10.1177/002215549704500301|pmid=9071315 }}] |
|
In a paper published in the ''New England Journal of Medicine'', Cote and colleagues identified nuclear p53 accumulation as an independent predictor of poor outcomes in bladder-confined transitional-cell carcinoma,[{{Cite journal|url=http://www.nejm.org/doi/abs/10.1056/NEJM199411103311903|title=Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer|first1=David|last1=Esrig|first2=Donald|last2=Elmajian|first3=Susan|last3=Groshen|first4=John A.|last4=Freeman|first5=John P.|last5=Stein|first6=Su-Chiu|last6=Chen|first7=Peter W.|last7=Nichols|first8=Donald G.|last8=Skinner|first9=Peter A.|last9=Jones|first10=Richard J.|last10=Cote|date=November 10, 1994|journal=New England Journal of Medicine|volume=331|issue=19|pages=1259–1264|via=CrossRef|doi=10.1056/NEJM199411103311903|pmid=7935683 }}] while also demonstrating genetic discrepancies between papillary and flat transitional cell carcinomas, indicating diverse pathways of tumor progression.[{{Cite web|url=https://aacrjournals.org/cancerres/article/54/3/784/500944/Two-Molecular-Pathways-to-Transitional-Cell|title=Two Molecular Pathways to Transitional Cell Carcinoma of the Bladder1 | Cancer Research | American Association for Cancer Research}}] He further showed that microcantilevers can detect [[prostate-specific antigen]] (PSA) in various concentrations, suggesting their potential for diagnosing [[prostate cancer]] and other diseases.[{{Cite journal|url=https://www.nature.com/articles/nbt0901-856|title=Bioassay of prostate-specific antigen (PSA) using microcantilevers|first1=Guanghua|last1=Wu|first2=Ram H.|last2=Datar|first3=Karolyn M.|last3=Hansen|first4=Thomas|last4=Thundat|first5=Richard J.|last5=Cote|first6=Arun|last6=Majumdar|date=September 30, 2001|journal=Nature Biotechnology|volume=19|issue=9|pages=856–860|via=www.nature.com|doi=10.1038/nbt0901-856|pmid=11533645 |url-access=subscription}}] Later, alongside Shan-Rong Shi and Clive Taylor, he reviewed the antigen retrieval technique in immunohistochemical staining, emphasizing the need for standardized protocols and optimal retrieval methods.[{{Cite journal|url=http://journals.sagepub.com/doi/10.1177/002215549704500301|title=Antigen Retrieval Immunohistochemistry: Past, Present, and Future|first1=Shan-Rong|last1=Shi|first2=Richard J.|last2=Cote|first3=Clive R.|last3=Taylor|date=March 31, 1997|journal=Journal of Histochemistry & Cytochemistry|volume=45|issue=3|pages=327–343|via=CrossRef|doi=10.1177/002215549704500301|pmid=9071315 }}] |
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
